References
1. Dowell D, Haegerich TM, Chou R. CDC guideline for prescribing opioids
for chronic pain - United States, 2016. MMWR Recomm Reports .
2016;65(1):1-49. doi:10.15585/mmwr.rr6501e1
2. Chou R, Turner JA, Devine EB, et al. The effectiveness and risks of
long-term opioid therapy for chronic pain: A systematic review for a
national institutes of health pathways to prevention workshop. Ann
Intern Med . 2015;162(4):276-286. doi:10.7326/M14-2559
3. Busse JW, Craigie S, Juurlink DN, et al. Guideline for opioid therapy
and chronic noncancer pain. CMAJ . 2017;189(18):E659-E666.
doi:10.1503/cmaj.170363
4. Inturrisi CE. Clinical Pharmacology of Opioids for Pain .;
2002.
5. WHO | Information sheet on opioid overdose. WHO .
2018.
6. Han B, Compton WM, Blanco C, Crane E, Lee J, Jones CM. Prescription
opioid use, misuse, and use disorders in U.S. Adults: 2015 national
survey on drug use and health. Ann Intern Med .
2017;167(5):293-301. doi:10.7326/M17-0865
7. The Health Effects of Cannabis and Cannabinoids: The Current State of
Evidence and Recommendations for Research : Health and Medicine
Division.
http://www.nationalacademies.org/hmd/Reports/2017/health-effects-of-cannabis-and-cannabinoids.aspx.
Accessed December 1, 2019.
8. (No Title).
https://www.canada.ca/content/dam/hc-sc/documents/services/drugs-medication/cannabis/information-medical-practitioners/information-health-care-professionals-cannabis-cannabinoids-eng.pdf.
Accessed December 1, 2019.
9. Thompson GR, Rosenkrantz H, Schaeppi UH, Braude MC. Comparison of
acute oral toxicity of cannabinoids in rats, dogs and monkeys.Toxicol Appl Pharmacol . 1973;25(3):363-372.
doi:10.1016/0041-008X(73)90310-4
10. Ware MA, St Arnaud-Trempe E. The abuse potential of the synthetic
cannabinoid nabilone. Addiction . 2010;105(3):494-503.
doi:10.1111/j.1360-0443.2009.02776.x
11. Katsidoni V, Anagnostou I, Panagis G. Cannabidiol inhibits the
reward-facilitating effect of morphine: Involvement of 5-HT1A receptors
in the dorsal raphe nucleus. Addict Biol . 2013;18(2):286-296.
doi:10.1111/j.1369-1600.2012.00483.x
12. Cooper ZD, Bedi G, Ramesh D, Balter R, Comer SD, Haney M. Impact of
co-administration of oxycodone and smoked cannabis on analgesia and
abuse liability. Neuropsychopharmacology . 2018.
doi:10.1038/s41386-018-0011-2
13. Nielsen S, Sabioni P, Trigo JM, et al. Opioid-sparing effect of
cannabinoids: A systematic review and meta-analysis.Neuropsychopharmacology . 2017. doi:10.1038/npp.2017.51
14. Lake S, Walsh Z, Kerr T, et al. Frequency of cannabis and illicit
opioid use among people who use drugs and report chronic pain: A
longitudinal analysis. Alegria M, ed. PLOS Med .
2019;16(11):e1002967. doi:10.1371/journal.pmed.1002967
15. Abrams DI, Couey P, Shade SB, Kelly ME, Benowitz NL.
Cannabinoid-opioid interaction in chronic pain. Clin Pharmacol
Ther . 2011;90(6):844-851. doi:10.1038/clpt.2011.188
16. Ware MA, Wang T, Shapiro S, Collet JP. Cannabis for the Management
of Pain: Assessment of Safety Study (COMPASS). J Pain .
2015;16(12):1233-1242. doi:10.1016/j.jpain.2015.07.014
17. Haroutounian S, Ratz Y, Ginosar Y, et al. The Effect of Medicinal
Cannabis on Pain and Quality-of-Life Outcomes in Chronic Pain: A
Prospective Open-label Study. Clin J Pain . 2016;32(12):1036-1043.
doi:10.1097/AJP.0000000000000364
18. Sagy I, Bar-Lev Schleider L, Abu-Shakra M, Novack V. Safety and
Efficacy of Medical Cannabis in Fibromyalgia. J Clin Med .
2019;8(6):807. doi:10.3390/jcm8060807
19. Rod K. A Pilot Study of a Medical Cannabis - Opioid Reduction
Program. Am J Psychiatry Neurosci . 2019;7(3):74.
doi:10.11648/j.ajpn.20190703.14
20. Abuhasira R, Schleider LBL, Mechoulam R, Novack V. Epidemiological
characteristics, safety and efficacy of medical cannabis in the elderly.Eur J Intern Med . 2018;49:44-50. doi:10.1016/j.ejim.2018.01.019
21. Lucas P, Walsh Z. Medical cannabis access, use, and substitution for
prescription opioids and other substances: A survey of authorized
medical cannabis patients. Int J Drug Policy . 2017;42:30-35.
doi:10.1016/j.drugpo.2017.01.011
22. Lucas P, Baron EP, Jikomes N. Medical cannabis patterns of use and
substitution for opioids & other pharmaceutical drugs, alcohol,
tobacco, and illicit substances; results from a cross-sectional survey
of authorized patients. Harm Reduct J . 2019;16(1):9.
doi:10.1186/s12954-019-0278-6
23. Lucas P, Walsh Z, Crosby K, et al. Substituting cannabis for
prescription drugs, alcohol and other substances among medical cannabis
patients: The impact of contextual factors. Drug Alcohol Rev .
2016;35(3):326-333. doi:10.1111/dar.12323
24. Wildes M, Bigand TL, Layton ME, Wilson M. Cannabis Use and Cognition
in Adults Prescribed Opioids for Persistent Pain. Pain Manag
Nurs . 2019. doi:10.1016/j.pmn.2019.06.014
25. Campbell G, Hall WD, Peacock A, et al. Effect of cannabis use in
people with chronic non-cancer pain prescribed opioids: findings from a
4-year prospective cohort study. Lancet Public Heal .
2018;3(7):e341-e350. doi:10.1016/S2468-2667(18)30110-5
26. Reiman A, Welty M, Solomon P. Cannabis as a Substitute for
Opioid-Based Pain Medication: Patient Self-Report.
doi:10.1089/can.2017.0012
27. Boehnke KF, Litinas E, Clauw DJ. Medical Cannabis Use Is Associated
with Decreased Opiate Medication Use in a Retrospective Cross-Sectional
Survey of Patients with Chronic Pain. J Pain . 2016;17(6):739-744.
doi:10.1016/j.jpain.2016.03.002
28. Hamilton I, Monaghan M. Cannabis and Psychosis: Are We any Closer to
Understanding the Relationship? Curr Psychiatry Rep . 2019;21(7).
doi:10.1007/s11920-019-1044-x
29. Lev-Ran S, Roerecke M, Le Foll B, George TP, McKenzie K, Rehm J. The
association between cannabis use and depression: A systematic review and
meta-analysis of longitudinal studies. Psychol Med .
2014;44(4):797-810. doi:10.1017/S0033291713001438
30. Fischer B, Russell C, Sabioni P, et al. Lower-Risk Cannabis Use
Guidelines: A Comprehensive Update of Evidence and Recommendations.Am J Public Health . 2017;107(8):e1-e12.
doi:10.2105/AJPH.2017.303818
31. Volkow ND, Baler RD, Compton WM, Weiss SRB. Adverse health effects
of marijuana use. N Engl J Med . 2014;370(23):2219-2227.
doi:10.1056/NEJMra1402309
32. Iffland K, Grotenhermen F. An Update on Safety and Side Effects of
Cannabidiol: A Review of Clinical Data and Relevant Animal Studies.Cannabis Cannabinoid Res . 2017;2(1):139-154.
doi:10.1089/can.2016.0034
33. Whiting PF, Wolff RF, Deshpande S, et al. Cannabinoids for medical
use: A systematic review and meta-analysis. JAMA - J Am Med
Assoc . 2015;313(24):2456-2473. doi:10.1001/jama.2015.6358
34. Russo EB. Cannabis and Pain. Pain Med . September 2019.
doi:10.1093/pm/pnz227
35. Hasson F, Keeney S, McKenna H. Research guidelines for the Delphi
survey technique. J Adv Nurs . 2000;32(4):1008-1015.
doi:10.1046/j.1365-2648.2000.t01-1-01567.x
36. Starrels JL, Young SR, Azari SS, et al. Disagreement and Uncertainty
Among Experts About how to Respond to Marijuana Use in Patients on
Long-term Opioids for Chronic Pain: Results of a Delphi Study.Pain Med . August 2019. doi:10.1093/pm/pnz153
37. Dalkey N. An experimental study of group opinion: The Delphi method.Futures . 1969. doi:10.1016/S0016-3287(69)80025-X
38. Dalkey N, Helmer O. An Experimental Application of the DELPHI Method
to the Use of Experts. Manage Sci . 1963. doi:10.1287/mnsc.9.3.458
39. Saad F, Canil C, Finelli A, et al. A Canadian consensus forum on the
management of patients with advanced prostate cancer. Can Urol
Assoc J . 2019;14(4). doi:10.5489/cuaj.6082
40. PAINWeek 2019 Accepted Abstracts by PAINWeek - issuu.
https://issuu.com/painweek/docs/accepted_full_abstracts_by_poster_number_8.26.19.
Accessed December 16, 2019.
41. Gillessen S, Attard G, Beer TM, et al. Management of Patients with
Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer
Consensus Conference APCCC 2017 [Figure presented]. In:European Urology . ; 2018. doi:10.1016/j.eururo.2017.06.002
42. Eubank BH, Mohtadi NG, Lafave MR, et al. Using the modified Delphi
method to establish clinical consensus for the diagnosis and treatment
of patients with rotator cuff pathology. BMC Med Res Methodol .
2016;16(1). doi:10.1186/s12874-016-0165-8
43. Stewart D, Gibson-Smith K, MacLure K, et al. A modified Delphi study
to determine the level of consensus across the European Union on the
structures, processes and desired outcomes of the management of
polypharmacy in older people. Leong C, ed. PLoS One .
2017;12(11):e0188348. doi:10.1371/journal.pone.0188348
44. Diamond IR, Grant RC, Feldman BM, et al. Defining consensus: A
systematic review recommends methodologic criteria for reporting of
Delphi studies. J Clin Epidemiol . 2014;67(4):401-409.
doi:10.1016/j.jclinepi.2013.12.002
45. McGuire P, Robson P, Cubala WJ, et al. Cannabidiol (CBD) as an
adjunctive therapy in schizophrenia: A multicenter randomized controlled
trial. Am J Psychiatry . 2018;175(3):225-231.
doi:10.1176/appi.ajp.2017.17030325
46. Boggs DL, Surti T, Gupta A, et al. The effects of cannabidiol (CBD)
on cognition and symptoms in outpatients with chronic schizophrenia a
randomized placebo controlled trial. Psychopharmacology (Berl) .
2018;235(7):1923-1932. doi:10.1007/s00213-018-4885-9
47. Dowell D, Haegerich T, Chou R. No Shortcuts to Safer Opioid
Prescribing. N Engl J Med . 2019;380(24):2285-2287.
doi:10.1056/NEJMp1904190
48. Tick H, Nielsen A, Pelletier KR, et al. Evidence-Based
Nonpharmacologic Strategies for Comprehensive Pain Care: The Consortium
Pain Task Force White Paper. Explore . 2018;14(3):177-211.
doi:10.1016/j.explore.2018.02.001
49. PAIN MANAGEMENT BEST PRACTICES INTER-AGENCY TASK FORCE
REPORT .; 2019.
50. Devinsky O, Cross JH, Laux L, et al. Trial of Cannabidiol for
Drug-Resistant Seizures in the Dravet Syndrome. N Engl J Med .
2017;376(21):2011-2020. doi:10.1056/NEJMoa1611618
51. Devinsky O, Patel AD, Cross JH, et al. Effect of Cannabidiol on Drop
Seizures in the Lennox–Gastaut Syndrome. N Engl J Med .
2018;378(20):1888-1897. doi:10.1056/NEJMoa1714631
52. Arain M, Haque M, Johal L, et al. Maturation of the adolescent
brain. Neuropsychiatr Dis Treat . 2013;9:449-461.
doi:10.2147/NDT.S39776
53. Dalton WS, Martz R, Lemberger L, Rodda BE, Forney RB. Influence of
cannabidiol on delta-9-tetrahydrocannabinol effects. Clin
Pharmacol Ther . 1976;19(3):300-309. doi:10.1002/cpt1976193300
54. Capano A, Weaver R, Burkman E. Evaluation of the effects of CBD hemp
extract on opioid use and quality of life indicators in chronic pain
patients: a prospective cohort study. Postgrad Med . November
2019:1-6. doi:10.1080/00325481.2019.1685298
55. Hurd YL, Spriggs S, Alishayev J, et al. Cannabidiol for the
reduction of cue-induced craving and anxiety in drug-abstinent
individuals with heroin use disorder: A double-blind randomized
placebo-controlled trial. Am J Psychiatry . 2019;176(11):911-922.
doi:10.1176/appi.ajp.2019.18101191
56. Li X, Vigil JM, Stith SS, Brockelman F, Keeling K, Hall B. The
effectiveness of self-directed medical cannabis treatment for pain.Complement Ther Med . 2019;46:123-130.
doi:10.1016/j.ctim.2019.07.022
57. Stith SS, Vigil JM, Brockelman F, Keeling K, Hall B. The Association
between Cannabis Product Characteristics and Symptom Relief. Sci
Rep . 2019;9(1). doi:10.1038/s41598-019-39462-1
58. Wade DT, Makela P, Robson P, House H, Bateman C. Do cannabis-based
medicinal extracts have general or specific effects on symptoms in
multiple sclerosis? A double-blind, randomized, placebo-controlled study
on 160 patients. Mult Scler . 2004;10(4):434-441.
doi:10.1191/1352458504ms1082oa
59. Wade DT, Robson P, House H, Makela P, Aram J. A preliminary
controlled study to determine whether whole-plant cannabis extracts can
improve intractable neurogenic symptoms. Clin Rehabil .
2003;17(1):21-29. doi:10.1191/0269215503cr581oa
60. Hunter D, Oldfield G, Tich N, Messenheimer J, Sebree T. Synthetic
transdermal cannabidiol for the treatment of knee pain due to
osteoarthritis. Osteoarthr Cartil . 2018;26:S26.
doi:10.1016/j.joca.2018.02.067
61. Xu DH, Cullen BD, Tang M, Fang Y. The Effectiveness of Topical
Cannabidiol Oil in Symptomatic Relief of Peripheral Neuropathy of the
Lower Extremities. Curr Pharm Biotechnol . 2019;20.
doi:10.2174/1389201020666191202111534
62. Andreae MH, Carter GM, Shaparin N, et al. Inhaled Cannabis for
Chronic Neuropathic Pain: A Meta-analysis of Individual Patient Data.J Pain . 2015;16(12):1221-1232. doi:10.1016/j.jpain.2015.07.009
63. Beal JE, Olson R, Laubenstein L, et al. Dronabinol as a treatment
for anorexia associated with weight loss in patients with AIDS. J
Pain Symptom Manage . 1995;10(2):89-97. doi:10.1016/0885-3924(94)00117-4
64. Matheson J, Sproule B, Di Ciano P, et al. Sex differences in the
acute effects of smoked cannabis: evidence from a human laboratory study
of young adults. Psychopharmacology (Berl) . 2019.
doi:10.1007/s00213-019-05369-y
65. Boehnke KF, Clauw DJ. Brief commentary: Cannabinoid dosing for
chronic pain management. Ann Intern Med . 2019;170(2):118.
doi:10.7326/M18-2972
66. Kuhathasan N, Dufort A, MacKillop J, Gottschalk R, Minuzzi L, Frey
BN. The use of cannabinoids for sleep: A critical review on clinical
trials. Exp Clin Psychopharmacol . 2019;27(4):383-401.
doi:10.1037/pha0000285
67. Manwell LA, Charchoglyan A, Brewer D, Matthews BA, Heipel H, Mallet
PE. A vapourized δ9-tetrahydrocannabinol (δ9-THC) delivery system part
I: Development and validation of a pulmonary cannabinoid route of
exposure for experimental pharmacology studies in rodents. J
Pharmacol Toxicol Methods . 2014;70(1):120-127.
doi:10.1016/j.vascn.2014.06.006
68. Layden JE, Ghinai I, Pray I, et al. Pulmonary Illness Related to
E-Cigarette Use in Illinois and Wisconsin — Preliminary Report.N Engl J Med . September 2019. doi:10.1056/nejmoa1911614
69. Kalininskiy A, Bach CT, Nacca NE, et al. E-cigarette, or vaping,
product use associated lung injury (EVALI): case series and diagnostic
approach. Lancet Respir Med . 2019;7(12):1017-1026.
doi:10.1016/S2213-2600(19)30415-1
70. Rubin R. HHS Guide for Tapering or Stopping Long-term Opioid Use.JAMA . 2019;322(20):1947. doi:10.1001/jama.2019.18979
71. CDC. HHS Guide for Clinicians on the Appropriate Dosage
Reduction or Discontinuation of Long-Term Opioid Analgesics .
72. Morris NP. Educating Physicians about Marijuana. JAMA Intern
Med . 2019;179(8):1017-1018. doi:10.1001/jamainternmed.2019.1529
73. Evanoff AB, Quan T, Dufault C, Awad M, Bierut LJ.
Physicians-in-training are not prepared to prescribe medical marijuana.Drug Alcohol Depend . 2017;180:151-155.
doi:10.1016/j.drugalcdep.2017.08.010